. Author manuscript; available in PMC: 2018 Oct 1.

Published in final edited form as: Cancer. 2017 Jun 22;123(19):3763–3771. doi: 10.1002/cncr.30818

Table 4.

Baseline Cost-Effectiveness Analysis and Probabilistic Sensitivity Analysis

Strategy	Baseline Model					PSA Model ICER 95% CI ($/QALY)
Strategy	Costs ($)	Incremental Costs ($)	Effectiveness (QALY)	Incremental Effectiveness	ICER ($/QALY)	PSA Model ICER 95% CI ($/QALY)
Active surveillance	219,761	-	13.50	-	-
BV consolidation	378,832	159,071	14.57	1.07	148,664	97,134 to 282,171

Abbreviations: PSA indicates probabilistic sensitivity analyses; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; CI, confidence interval; BV, brentuximab vedotin.